AR069062A1 - Anticuerpo anti-hepcidina - Google Patents
Anticuerpo anti-hepcidinaInfo
- Publication number
- AR069062A1 AR069062A1 ARP080104691A ARP080104691A AR069062A1 AR 069062 A1 AR069062 A1 AR 069062A1 AR P080104691 A ARP080104691 A AR P080104691A AR P080104691 A ARP080104691 A AR P080104691A AR 069062 A1 AR069062 A1 AR 069062A1
- Authority
- AR
- Argentina
- Prior art keywords
- lcdr1
- lcdr2
- hcdr1
- lcdr3
- hcdr2
- Prior art date
Links
- 229940066919 hepcidin Drugs 0.000 title abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- 102000009052 human hepcidin 25 Human genes 0.000 abstract 2
- 108700022871 human hepcidin 25 Proteins 0.000 abstract 2
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 abstract 1
- 102000001554 Hemoglobins Human genes 0.000 abstract 1
- 108010054147 Hemoglobins Proteins 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 238000004820 blood count Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000003743 erythrocyte Anatomy 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 238000005534 hematocrit Methods 0.000 abstract 1
- 102000018511 hepcidin Human genes 0.000 abstract 1
- 108060003558 hepcidin Proteins 0.000 abstract 1
- 238000003018 immunoassay Methods 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
- 210000001995 reticulocyte Anatomy 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Anticuerpo anti-hepcidina monoclonales que tienen una alta afinidad para hepcidina-25 humana y fuertes propiedades neutralizantes de hepcidina madura humana, que se enlaza selectivamente a hepcidina-25 humana con un KD de aproximadamente 800 pM o menos, como se determina por resonancia de plasmón de superficie (SPR) a 25ºC y comprende seis CDRs seleccionadas del grupo que consiste en: (i) LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, y HCDR3 que tienen las secuencias de aminoácido como se muestran en las SEC ID Nº 52, 60, 62, 65, 71, y 75, respectivamente; (ii) LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, y HCDR3 que tienen las secuencias de aminoácido como se muestran en las SEC ID Nº 42, 76, 62, 79, 87, y 46, respectivamente; (iii) LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, y HCDR3 que tienen las secuencias de aminoácido como se muestran en las SEC ID Nº 41, 53, 31, 63, 84, y 46, respectivamente; (iv) LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, y HCDR3 que tienen las secuencias de aminoácido como se muestran en las SEC ID Nº 43, 30, 31, 32, 44, y 46, respectivamente; (v) LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, y HCDR3 que tienen las secuencias de aminoácido como se muestran en las SEC ID Nº 43, 53, 61, 63, 85, y 46, respectivamente; y (vi) LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, y HCDR3 que tienen las secuencias de aminoácido como se muestran en las SEC ID Nº 43, 57, 61, 63, 84, y 46, respectivamente. Polinucleótido, vector de expresión recombinante y célula huésped correspondientes. Uso del anticuerpo para la preparación de un medicamento útil para el tratamiento y/o prevención de anemia, incrementar los niveles de hierro, conteo de reticulocito, conteo de células rojas de la sangre, hemoglobina, o hematocrito en suero, composición farmacéutica e inmunoensayo que lo comprende.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98491007P | 2007-11-02 | 2007-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069062A1 true AR069062A1 (es) | 2009-12-23 |
Family
ID=40383701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104691A AR069062A1 (es) | 2007-11-02 | 2008-10-27 | Anticuerpo anti-hepcidina |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US7820163B2 (es) |
| EP (2) | EP2209806B1 (es) |
| JP (1) | JP5469076B2 (es) |
| KR (2) | KR101335059B1 (es) |
| CN (1) | CN103492414B (es) |
| AR (1) | AR069062A1 (es) |
| AU (1) | AU2008318850B2 (es) |
| BR (1) | BRPI0819211A2 (es) |
| CA (1) | CA2704527C (es) |
| CL (2) | CL2008003190A1 (es) |
| CO (1) | CO6231037A2 (es) |
| CR (1) | CR11414A (es) |
| CY (1) | CY1113630T1 (es) |
| DK (1) | DK2209806T3 (es) |
| DO (2) | DOP2010000123A (es) |
| EA (1) | EA023406B1 (es) |
| ES (1) | ES2392123T3 (es) |
| HR (1) | HRP20120870T1 (es) |
| IL (1) | IL205355A (es) |
| JO (1) | JO2828B1 (es) |
| MA (1) | MA31886B1 (es) |
| MX (1) | MX2010004841A (es) |
| MY (1) | MY155708A (es) |
| NZ (2) | NZ598391A (es) |
| PE (1) | PE20091261A1 (es) |
| PL (1) | PL2209806T3 (es) |
| PT (1) | PT2209806E (es) |
| RS (1) | RS52592B (es) |
| SI (1) | SI2209806T1 (es) |
| TN (1) | TN2010000201A1 (es) |
| TW (1) | TWI409276B (es) |
| UA (1) | UA98983C2 (es) |
| WO (1) | WO2009058797A1 (es) |
| ZA (1) | ZA201003025B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2008047485A1 (ja) * | 2006-10-17 | 2010-02-18 | 直久 友杉 | 活性型ヘプシジンを指標とした、鉄代謝異常の診断方法 |
| MX2009008104A (es) | 2007-02-02 | 2009-08-07 | Amgen Inc | Hepcidina, antagonistas de hepcidina y metodos de uso. |
| WO2008146903A1 (ja) * | 2007-05-31 | 2008-12-04 | Naohisa Tomosugi | 活性型ヘプシジンを指標とした、急性虚血性疾患の診断方法 |
| AR069062A1 (es) | 2007-11-02 | 2009-12-23 | Lilly Co Eli | Anticuerpo anti-hepcidina |
| EP2620448A1 (en) * | 2008-05-01 | 2013-07-31 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| KR101462307B1 (ko) * | 2008-08-06 | 2014-11-17 | 일라이 릴리 앤드 캄파니 | 항-헵시딘-25 선택적 항체 및 그의 용도 |
| DE102009034150A1 (de) | 2009-07-20 | 2011-01-27 | Fresenius Medical Care Deutschland Gmbh | Adsorbens zur Adsorption von Hepcidin |
| WO2011020886A1 (de) | 2009-08-20 | 2011-02-24 | Vifor (International) Ag | Neue chinolin-hepcidin-antagonisten |
| AR077958A1 (es) | 2009-08-27 | 2011-10-05 | Vifor Int Ag | Quinoxalinonas antagonistas de la hepcidina |
| AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
| JP2013503835A (ja) | 2009-09-07 | 2013-02-04 | ヴィフォール （インターナショナル） アクチェンゲゼルシャフト | 新規なエタンジアミン系ヘプシジン拮抗薬 |
| TW201111379A (en) | 2009-09-09 | 2011-04-01 | Vifor Int Ag | Novel thiazole-and oxazole-hepcidine-antagonists |
| WO2011071368A1 (en) | 2009-12-11 | 2011-06-16 | Umc St. Radboud | Method for measuring hepcidin |
| DK2606061T3 (da) * | 2010-08-16 | 2017-11-06 | Pieris Pharmaceuticals Gmbh | Bindingsproteiner til hepcidin |
| US20120214803A1 (en) | 2011-02-18 | 2012-08-23 | Vifor (International) Ag | Novel Sulfonaminoquinoline Hepcidin Antagonists |
| AU2012350654C1 (en) | 2011-12-12 | 2018-05-10 | Pieris Ag | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation |
| JP6463331B2 (ja) * | 2013-03-15 | 2019-01-30 | イントリンシック ライフサイエンシズ リミテッド ライアビリティ カンパニー | 抗ヘプシジン抗体およびその使用 |
| AU2015321462B2 (en) | 2014-09-22 | 2020-04-30 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| CN104945497B (zh) * | 2014-11-21 | 2018-04-03 | 南京国龙生物科技有限公司 | 一种新型抗菌肽Hep‑W及其制备方法和应用 |
| WO2016137950A1 (en) * | 2015-02-24 | 2016-09-01 | Rpeptide, Llc | Anti-tau antibodies |
| WO2016146587A1 (en) | 2015-03-13 | 2016-09-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Hepcidin antagonists for use in the treatment of inflammation |
| TWI789343B (zh) | 2016-02-01 | 2023-01-11 | 丹麥商碩騰丹麥有限公司 | 微流體分析系統、執行分析的微流體匣及方法 |
| WO2018234538A1 (en) | 2017-06-23 | 2018-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Hepcidin antagonist or agonist for use in the treatment of dysregulation of mo and/or mn metabolism |
| ES2759622T3 (es) * | 2017-10-02 | 2020-05-11 | Certest Biotec S L | Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter |
| JP2022549506A (ja) | 2019-09-27 | 2022-11-25 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症および関連状態を処置するための方法 |
| EP4149548A4 (en) | 2020-05-13 | 2024-05-08 | Disc Medicine, Inc. | ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| CN117903311B (zh) * | 2024-03-20 | 2024-10-25 | 湖南卓润生物科技有限公司 | sST2特异性结合蛋白及其制备方法和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1210418B1 (en) | 1999-06-02 | 2010-08-18 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6262247B1 (en) | 1999-08-30 | 2001-07-17 | Incyte Genomics, Inc. | Polycyclic aromatic hydrocarbon induced molecules |
| JP4944360B2 (ja) | 2001-05-25 | 2012-05-30 | アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） | 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用 |
| CN1173737C (zh) | 2002-10-21 | 2004-11-03 | 钱忠明 | Hepcidin(海魄喜定)在制药中的应用 |
| EP1578254B1 (en) | 2002-11-19 | 2013-03-06 | DRG International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor |
| US8017737B2 (en) | 2002-11-19 | 2011-09-13 | Hasan Kulaksiz | Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor |
| US7411048B2 (en) | 2002-11-19 | 2008-08-12 | Drg International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids |
| CA2537668A1 (en) | 2003-09-29 | 2005-04-14 | Biosite Incorporated | Methods and compositions for the diagnosis of sepsis |
| US7723063B2 (en) * | 2004-04-28 | 2010-05-25 | Intrinsic Lifesciences | Methods for measuring levels of bioactive human hepcidin |
| WO2006046935A1 (en) | 2004-10-22 | 2006-05-04 | Applied Molecular Evolution, Inc | Methods of optimizing antibody variable region binding affinity |
| WO2006062685A2 (en) | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| NZ560976A (en) | 2005-03-11 | 2011-06-30 | Univ Johns Hopkins | Biomarkers for ovarian cancer and endometrial cancer: hepcidin |
| MX2009008104A (es) | 2007-02-02 | 2009-08-07 | Amgen Inc | Hepcidina, antagonistas de hepcidina y metodos de uso. |
| CN101903044A (zh) | 2007-10-02 | 2010-12-01 | 国家健康与医学研究院 | 对人铁调素具有特异性的抗原结合蛋白 |
| AR069062A1 (es) | 2007-11-02 | 2009-12-23 | Lilly Co Eli | Anticuerpo anti-hepcidina |
| EP2620448A1 (en) | 2008-05-01 | 2013-07-31 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| KR101462307B1 (ko) * | 2008-08-06 | 2014-11-17 | 일라이 릴리 앤드 캄파니 | 항-헵시딘-25 선택적 항체 및 그의 용도 |
-
2008
- 2008-10-27 AR ARP080104691A patent/AR069062A1/es unknown
- 2008-10-27 CL CL2008003190A patent/CL2008003190A1/es unknown
- 2008-10-27 JO JO2008486A patent/JO2828B1/en active
- 2008-10-27 PE PE2008001837A patent/PE20091261A1/es not_active Application Discontinuation
- 2008-10-27 TW TW097141237A patent/TWI409276B/zh not_active IP Right Cessation
- 2008-10-29 HR HRP20120870AT patent/HRP20120870T1/hr unknown
- 2008-10-29 RS RS20120466A patent/RS52592B/sr unknown
- 2008-10-29 NZ NZ598391A patent/NZ598391A/xx not_active IP Right Cessation
- 2008-10-29 SI SI200830773T patent/SI2209806T1/sl unknown
- 2008-10-29 MY MYPI2010001992A patent/MY155708A/en unknown
- 2008-10-29 ES ES08844586T patent/ES2392123T3/es active Active
- 2008-10-29 US US12/260,125 patent/US7820163B2/en not_active Expired - Fee Related
- 2008-10-29 PT PT08844586T patent/PT2209806E/pt unknown
- 2008-10-29 KR KR1020107009633A patent/KR101335059B1/ko not_active Expired - Fee Related
- 2008-10-29 AU AU2008318850A patent/AU2008318850B2/en not_active Ceased
- 2008-10-29 WO PCT/US2008/081493 patent/WO2009058797A1/en not_active Ceased
- 2008-10-29 EP EP08844586A patent/EP2209806B1/en active Active
- 2008-10-29 KR KR1020127023660A patent/KR20120107145A/ko not_active Withdrawn
- 2008-10-29 PL PL08844586T patent/PL2209806T3/pl unknown
- 2008-10-29 DK DK08844586.1T patent/DK2209806T3/da active
- 2008-10-29 BR BRPI0819211-1A patent/BRPI0819211A2/pt not_active IP Right Cessation
- 2008-10-29 CA CA2704527A patent/CA2704527C/en not_active Expired - Fee Related
- 2008-10-29 EA EA201070553A patent/EA023406B1/ru not_active IP Right Cessation
- 2008-10-29 NZ NZ584997A patent/NZ584997A/en not_active IP Right Cessation
- 2008-10-29 CN CN200880114428.1A patent/CN103492414B/zh not_active Expired - Fee Related
- 2008-10-29 JP JP2010532186A patent/JP5469076B2/ja not_active Expired - Fee Related
- 2008-10-29 MX MX2010004841A patent/MX2010004841A/es active IP Right Grant
- 2008-10-29 EP EP12172307.6A patent/EP2527368B1/en active Active
- 2008-10-29 UA UAA201005156A patent/UA98983C2/uk unknown
-
2010
- 2010-04-22 CO CO10047542A patent/CO6231037A2/es active IP Right Grant
- 2010-04-26 IL IL205355A patent/IL205355A/en not_active IP Right Cessation
- 2010-04-26 DO DO2010000123A patent/DOP2010000123A/es unknown
- 2010-04-30 TN TN2010000201A patent/TN2010000201A1/fr unknown
- 2010-04-30 ZA ZA2010/03025A patent/ZA201003025B/en unknown
- 2010-04-30 MA MA32811A patent/MA31886B1/fr unknown
- 2010-05-05 CR CR11414A patent/CR11414A/es not_active IP Right Cessation
- 2010-08-31 US US12/872,172 patent/US8329174B2/en active Active
-
2012
- 2012-06-22 CL CL2012001710A patent/CL2012001710A1/es unknown
- 2012-10-19 CY CY20121100986T patent/CY1113630T1/el unknown
- 2012-12-07 US US13/708,059 patent/US8765129B2/en active Active
-
2013
- 2013-09-11 DO DO2013000205A patent/DOP2013000205A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069062A1 (es) | Anticuerpo anti-hepcidina | |
| NZ590863A (en) | Anti-hepcidin-25 selective antibodies and uses thereof | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| IL259036A (en) | asct2-specific binding molecules and their uses | |
| HRP20151019T1 (hr) | PROTUTIJELA PROTIV c-MET | |
| ES2608381T3 (es) | Anticuerpos anti-BMP-6 | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| RU2013125306A (ru) | Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| JP2017505125A5 (es) | ||
| RU2018106364A (ru) | Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| JP2015535828A5 (es) | ||
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| NZ592436A (en) | Treatment with anti-alpha2 integrin antibodies | |
| JP2013543384A5 (es) | ||
| AR125212A1 (es) | Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas | |
| UY39878A (es) | Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma | |
| CN114762678B (zh) | 抗tigit抗体药物组合物及其用途 | |
| HRP20160302T1 (hr) | Monoklonska protutijela protiv feroportina 1 i njihova upotreba | |
| JP2017511152A5 (es) | ||
| JP2012510814A5 (es) | ||
| IL278323B2 (en) | Antibodies directed against glycoprotein IV | |
| ME02063B (me) | Protutijela koja se vezu na tgf-alfa i epiregulin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |